Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05821101 · ClinicalTrials.gov registry record · NA
Clinical Outcomes of Clareon Vivity Intraocular Lens With Mini-Monovision Approach
A NA study of Aphakia, Postcataract, sponsored by Debbie S. Kuo, MD.
- Active
- Registry status
- NA
- Development phase
- 30
- Enrollment target
- 1
- Study location
NCT05821101: Active NA study of Aphakia, Postcataract, sponsored by Debbie S. Kuo, MD.
NCT05821101 is a NA study of Aphakia, Postcataract that is active but no longer recruiting, run by Debbie S. Kuo, MD. The registered enrollment target is 30 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05821101, a NA study of Aphakia, Postcataract, is active but no longer recruiting, sponsored by Debbie S. Kuo, MD.
- ACTIVE NOT RECRUITING
- Registry status
- NA
- Development phase
- 30 participants
- Enrollment target
- 1
- Study location
Study Summary
Purpose is to study the clinical outcomes of Clareon Vivity and Clareon Vivity Toric intraocular lens (IOL) implants in patients who are planning to have cataract surgery in both eyes with a mini-monovision approach.
Primary Outcome
Increase in ability to see over a broad range of vision without glasses
Conditions Studied
Interventions
- DEVICE Clareon Vivity and Clareon Vivity Toric IOLs targeted for mini-monovision with dominant eye set at emmetropia and non-dominant eye at -0.50.
Study Locations (1)
California
- Palo Alto Medical Foundation - Palo Alto
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2023-04-06 |
| Est. Completion | 2026-06 |
| Phase | NA |
What the registry record for NCT05821101 still lists
NCT05821101 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower).
The record links to 1 condition, with Aphakia, Postcataract appearing as the primary indexed condition, and to 1 intervention - of which Clareon Vivity and Clareon Vivity Toric IOLs targeted for mini-monovision with dominant eye set at emmetropia and non-dominant eye at -0.50. is the first listed.
NCT05821101 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT05821101 about?
NCT05821101 is a clinical study titled "Clinical Outcomes of Clareon Vivity Intraocular Lens With Mini-Monovision Approach". Purpose is to study the clinical outcomes of Clareon Vivity and Clareon Vivity Toric intraocular lens (IOL) implants in patients who are planning to have cataract surgery in both eyes with a mini-monovision approach.
What is the current status of trial NCT05821101?
This trial is currently active not recruiting. It is a NA study. The enrollment target is 30 participants. The study started on 2023-04-06. Estimated completion is 2026-06.
What conditions does trial NCT05821101 study?
This clinical trial studies the following conditions: Aphakia, Postcataract.
What interventions are being tested in trial NCT05821101?
The interventions under investigation include: Clareon Vivity and Clareon Vivity Toric IOLs targeted for mini-monovision with dominant eye set at emmetropia and non-dominant eye at -0.50. (DEVICE).
Who is sponsoring clinical trial NCT05821101?
This trial is sponsored by Debbie S. Kuo, MD, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05821101 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05821101's enrollment target sits among peer trials
30 1593rd of 2000 higher than 299 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI